and avoiding spicy, high-fat, or high-fiber foods, particularly during the first few days of therapy
There are several reasons your doctor might recommend you avoid GLP-1s
Global Weight-Loss Deal Activity in 2025 H1: Partnerships and New Drug Investments In H1 2025, the weight-loss sector and metabolic diseases saw a flurry of dealmaking
Its extended half-life of approximately 4.7 days is attributed to its structural design, discussed in the large molecule conjugation section of this paper
#Immunology #Innovation #BiotechM&A #PharmaStrategy #Type2Inflammation To view or add a comment, sign in Drug Discovery Digest | This Weeks Industry Roundup Obesity, Innovation & the Future of R&D Discovery on Target 2026 is comingregister by June 12 to take advantage of the next savings deadline: Here are four developments shaping the future of drug discovery and development Science & Clinical Updates The Next Wave of Obesity Drug Readouts Is Here With multiple companies racing to compete in the obesity market, recent clinical updates from Pfizer, Lilly, and Viking are helping define the next generation of weight-loss therapies and differentiation strategies
Oshi dietitians can work with you to: Ensure you stay nourished and offer practical tips for navigating common GLP-1 side effects Build personalized meal plans that fit your lifestyle and medication schedule Guide you through small, sustainable changes to help you feel your best And so much more